UK Markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
56.72+1.98 (+3.62%)
At close: 4:00PM EDT

56.72 0.00 (0.00%)
After hours: 4:03PM EDT

Currency in USD

Valuation measures

Market cap (intra-day) 55.8B
Enterprise value 35.33B
Trailing P/E N/A
Forward P/E 1-101.29
PEG ratio (5-yr expected) 1-25.27
Price/sales (ttm)46.92
Price/book (mrq)11.76
Enterprise value/revenue 343.13
Enterprise value/EBITDA 6-189.45

Trading information

Stock price history

Beta (5Y monthly) 1.63
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 373.72
52-week low 319.51
50-day moving average 343.15
200-day moving average 340.37

Share statistics

Avg vol (3-month) 31.46M
Avg vol (10-day) 31.56M
Shares outstanding 5102.29M
Float 99.53M
% held by insiders 12.76%
% held by institutions 163.91%
Shares short (29 Sep 2020) 49.01M
Short ratio (29 Sep 2020) 43.75
Short % of float (29 Sep 2020) 412.14%
Short % of shares outstanding (29 Sep 2020) 48.81%
Shares short (prior month 30 Aug 2020) 49.42M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 316 Nov 2011

Financial highlights

Fiscal year

Fiscal year ends 29 Sep 2019
Most-recent quarter (mrq)29 Jun 2020

Profitability

Profit margin -19.75%
Operating margin (ttm)-27.01%

Management effectiveness

Return on assets (ttm)-4.68%
Return on equity (ttm)-6.80%

Income statement

Revenue (ttm)123.65M
Revenue per share (ttm)1.25
Quarterly revenue growth (yoy)-35.90%
Gross profit (ttm)168.8M
EBITDA -28.15M
Net income avi to common (ttm)-24.42M
Diluted EPS (ttm)-0.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)287.03M
Total cash per share (mrq)2.81
Total debt (mrq)21.37M
Total debt/equity (mrq)4.34
Current ratio (mrq)7.37
Book value per share (mrq)4.82

Cash flow statement

Operating cash flow (ttm)-70.73M
Levered free cash flow (ttm)-66.8M